ABCL
AbCellera Biologics Inc.
$11.82
+3.96%
2026-10-23
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Key Fundamentals
Forward P/E
-16.62
EPS (TTM)
$-0.54
ROE
-17.3%
Revenue Growth (YoY)
-76.3%
Profit Margin
-248.8%
Debt/Equity
15.13
Price/Book
4.34
Beta
1.32
Market Cap
$4.12B
Avg Volume (10D)
4.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$15.02
60D Low
$5.51
Avg Volume
6.7M
Latest Close
$11.82
Get breakout alerts for ABCL
Sign up for Breakout Scanner to receive daily notifications when ABCL triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
AbCellera Biologics Inc. (ABCL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABCL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABCL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.